UNSPSC 51124000: Antiarrythmic piperidines

This classification a family of hexahydropyridines that prevent or treat irregular heartbeat, disturbances of normal rhythmic heart beating, or normal operation of myocardial contraction, thus the term ANTIARRYTHMIC PIPERIDINES.

UNSPSC 51124000 Antiarrhythmic piperidines is a Class code covering emergency cardiac medications and antiarrhythmic agents purchased by state and local health systems, fire rescue departments, and public health programs. State and local governments procure these medications primarily for advanced life support protocols in emergency medical services, hospital intensive care units, and emergency departments. The solicitations show purchasing bodies acquiring specific formulations—adenosine, diltiazem, labetalol, and epinephrine—in injectable vial and ampule formats with firm expiration-date requirements, typically nine to twelve months from acceptance. Issuing bodies span city fire rescue departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). The City of Tampa and MMCAP appear as active recent buyers in this space.

Recent activity concentrates in Florida, Texas, and the upper Midwest. The City of Tampa's Purchasing Department issued Invitation for Bid (IFB) No. 26-P-00188 on April 24, 2026, for Advanced Life Support Medications (Epinephrine 1:10,000, Adenosine 6mg, Diltiazem 25mg, and Labetalol HCI 100mg), with sealed bids due April 8, 2026, and an estimated contract value of $40,000, including a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance issued Request for Proposal No. S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, requiring supply through three authorized wholesalers and effective July 1, 2026. The Texas Health and Human Services Commission released Request for Information No. HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription programs and vendor capabilities, signaling exploratory procurement strategy development preceding formal solicitation.